Clinical trial
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With…
NCT02684292 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT02684292 |
|---|---|
| Title | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) |
| Official title | A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hodgkin Lymphoma |
| Intervention type | Biological |
| Interventions | pembrolizumab, brentuximab vedotin |
| Enrollment | 304 |
| Start date | May 23, 2016 |
| Primary completion | Dec 10, 2025 |
| Completion | Dec 10, 2025 |
| First posted | Feb 17, 2016 |
| Last update posted | Dec 23, 2025 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: